103 related articles for article (PubMed ID: 15508942)
1. Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
Tseng MC; Chang KC
Acta Neurol Taiwan; 2004 Sep; 13(3):149-55. PubMed ID: 15508942
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of thrombolytic treatment for stroke.
Mar J; Begiristain JM; Arrazola A
Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
[TBL] [Abstract][Full Text] [Related]
4. A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.
Joo H; Wang G; George MG
Stroke Vasc Neurol; 2017; 2(2):73-83. PubMed ID: 28736623
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
[TBL] [Abstract][Full Text] [Related]
6. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.
Boudreau DM; Guzauskas G; Villa KF; Fagan SC; Veenstra DL
Ann Emerg Med; 2013 Jan; 61(1):46-55. PubMed ID: 22633340
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
[TBL] [Abstract][Full Text] [Related]
8. Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke.
Joo H; Wang G; George MG
Am J Prev Med; 2017 Dec; 53(6S2):S205-S212. PubMed ID: 29153122
[TBL] [Abstract][Full Text] [Related]
9. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
10. A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.
Kim AS; Nguyen-Huynh M; Johnston SC
Stroke; 2011 Jul; 42(7):2013-8. PubMed ID: 21636817
[TBL] [Abstract][Full Text] [Related]
11. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
Fryback DG; Chinnis JO; Ulvila JW
Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
13. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
[TBL] [Abstract][Full Text] [Related]
14. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke.
Moodie ML; Carter R; Mihalopoulos C; Thrift AG; Chambers BR; Donnan GA; Dewey HM
Stroke; 2004 May; 35(5):1041-6. PubMed ID: 15031457
[TBL] [Abstract][Full Text] [Related]
15. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
16. Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.
Fugate JE; Rabinstein AA
Mayo Clin Proc; 2014 Jul; 89(7):960-72. PubMed ID: 24775222
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke.
Araújo DV; Teich V; Passos RB; Martins SC
Arq Bras Cardiol; 2010 Jul; 95(1):12-20. PubMed ID: 20563521
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
[TBL] [Abstract][Full Text] [Related]
19. Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.
Te Ao B; Brown P; Fink J; Vivian M; Feigin V
Int J Stroke; 2015 Aug; 10(6):903-10. PubMed ID: 24206567
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
